

WHAT IS CLAIMED IS:

SUB  
B1

1. A method of inhibiting angiogenesis in a mammal comprising administering to the mammal an amount of an Eph receptor antagonist which is effective for inhibiting angiogenesis in the mammal.

5

2. The method of claim 1 wherein the mammal is a human.

3. The method of claim 1 wherein the antagonist binds an Eph receptor.

10 4. The method of claim 1 wherein the antagonist comprises an antibody.

5. The method of claim 4 wherein the antibody binds EphB4 receptor.

15 6. The method of claim 1 wherein the mammal is suffering from a disease or disorder characterized by undesirable or excessive vascularization or vascular permeability.

20 7. A method of treating cancer in a mammal comprising administering to the mammal a therapeutically effective amount of an Eph receptor antagonist.

8. The method of claim 7 wherein the antagonist binds an Eph receptor.

9. The method of claim 7 wherein the mammal has a solid malignant tumor.

25 10. The method of claim 7 wherein the antagonist is an antibody.

11. The method of claim 7 wherein the Eph receptor is EphB4.

30 12. The method of claim 7 wherein the mammal is a human.

13. The method of claim 7 wherein the antagonist binds Ephrin-B2.

14. A method of stimulating angiogenesis in a mammal comprising administering to the mammal an amount of an Eph receptor agonist which is effective for stimulating angiogenesis in the mammal.

5 15. The method of claim 14 wherein the mammal is a human.

16. The method of claim 14 wherein the antagonist comprises an agonist antibody.

17. The method of claim 16 wherein the agonist antibody binds an Eph receptor.

10

18. The method of claim 17 wherein the agonist antibody binds EphB4 receptor.

19. A method of treating a trauma to the vascular network in a mammal comprising administering to the mammal a therapeutically effective amount of an Eph receptor  
15 agonist.

20. An article of manufacture, comprising:

a container;

a label; and

20

a composition comprising an active agent contained within the container; wherein the label indicates that the composition can be used to treat a disease or disorder characterized by undesirable or excessive vascularization or vascular permeability and the active agent in the composition is an Eph receptor antagonist.

25

21. The article of manufacture of claim 20 further comprising instructions for administering the Eph receptor antagonist to a mammal to treat a disease or disorder in the mammal.

22. An article of manufacture, comprising:

30

a container;

a label; and

a composition comprising an active agent contained within the container; wherein the label indicates that the composition can be used to stimulate angiogenesis and the active agent in the composition is an Eph receptor agonist.